| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2024―Aug―29 |
The Global Virus Network: collaboration to address pandemic and regional threats |
Sten H. Vermund |
| 2 |
[GO] |
2024―Jul―25 |
COVID-19 epidemiology and variants: new challenges and future of the pandemic |
Ralph Baric |
| 3 |
[GO] |
2024―Jul―25 |
COVID-19 epidemiology and potential treatments: follow up interview |
Ralph Baric |
| 4 |
[GO] |
2024―Jul―25 |
FTIR spectroscopy for COVID-19 detection in saliva |
Andrei A. Bunaciu |
| 5 |
[GO] |
2024―Jul―25 |
The COVID-19 coronavirus outbreak: October 2020 update |
Jonathan Temte |
| 6 |
[GO] |
2024―Jul―25 |
The COVID-19 coronavirus outbreak: May 2020 update |
Jonathan Temte |
| 7 |
[GO] |
2024―Jul―25 |
The COVID-19 coronavirus outbreak: a current view |
Jonathan Temte |
| 8 |
[GO] |
2024―Jul―25 |
The COVID-19 coronavirus outbreak: March 2020 update |
Jonathan Temte |
| 9 |
[GO] |
2024―Jul―25 |
Remdesivir COVID-19 clinical trial |
Mahesh Parmar |
| 10 |
[GO] |
2024―Jul―25 |
Comparison of COVID-19 and seasonal HCoV pathologies and transfer to endemic state |
Rustom Antia |
| 11 |
[GO] |
2024―Jul―25 |
Risk of re-emergence of COVID-19 after exit from lockdown |
Leonardo Lopez |
| 12 |
[GO] |
2024―Jul―25 |
The anti-viral immune response to COVID-19 |
Danny Altmann |
| 13 |
[GO] |
2024―Jul―25 |
Convalescent plasma therapy as a treatment for COVID-19 |
Manu Shankar-Hari |
| 14 |
[GO] |
2024―Jul―25 |
Understanding statistics in epidemics and pandemics: lessons learned from COVID-19 |
Sarah Ransdell |
| 15 |
[GO] |
2024―Jul―25 |
Tuberculosis and COVID-19 |
Giovanni Battista Migliori |
| 16 |
[GO] |
2024―Jul―25 |
Human movement patterns and local spread of COVID-19 |
Ben Cowling |
| 17 |
[GO] |
2024―Jul―25 |
Triage and end of life care planning in COVID-19 |
Robin Taylor |
| 18 |
[GO] |
2024―Jul―25 |
Update on the SNG001 drug, an INFβ therapy for COVID-19 |
Stephen Holgate |
| 19 |
[GO] |
2024―Jul―25 |
Complement activation in COVID-19 |
Jeffrey Laurence |
| 20 |
[GO] |
2024―Jul―25 |
Human challenge trials for vaccines against COVID-19 |
Peter Smith |
| 21 |
[GO] |
2024―Jul―25 |
Interferon-α2b as a therapy for COVID-19 |
Eleanor N. Fish |
| 22 |
[GO] |
2024―Jul―25 |
Rheumatic diseases and COVID-19 |
Zachary Wallace |
| 23 |
[GO] |
2024―Jul―25 |
The neurological symptoms of COVID-19 |
Michael Zandi |
| 24 |
[GO] |
2024―Jul―25 |
Medical wearable devices for tracking symptoms of COVID-19 |
John Rogers |
| 25 |
[GO] |
2024―Jul―25 |
Development of PRO-140 (Leronlimab) as a treatment for COVID-19 |
Jacob Lalezari |
| 26 |
[GO] |
2024―Jul―25 |
The impact of COVID-19 in the elderly and in care homes |
David Strain |
| 27 |
[GO] |
2024―Jul―25 |
Impact of COVID-19 on neuropsychiatric disorders and mental health |
Anthony David |
| 28 |
[GO] |
2024―Jul―25 |
The COVID-19 outbreak: an update on the SARS-CoV-2 virus |
Ralph Baric |
| 29 |
[GO] |
2024―Jul―25 |
The COVID-19 outbreak: April 2021 update |
Jonathan Temte |
| 30 |
[GO] |
2024―Jul―25 |
Predicting COVID-19 outbreaks by measuring SARS-CoV-2 RNA in sewage sludge |
Jordan Peccia |
| 31 |
[GO] |
2024―Jul―25 |
Natural killer cells as COVID-19 therapy |
Philippa Kennedy |
| 32 |
[GO] |
2024―Jul―25 |
mRNA COVID-19 vaccine efficacy in recovered vs COVID-naive individuals |
E. John Wherry |
| 33 |
[GO] |
2024―Jul―25 |
Oxford/AstraZeneca COVID-19 vaccine trial: adverse patient event reports |
Saad Shakir |
| 34 |
[GO] |
2024―Jul―25 |
Planning and response to COVID-19: lessons from China and South-East Asia |
Annelies Wilder-Smith |
| 35 |
[GO] |
2024―Jul―25 |
COVID-19: the anti-viral immune response |
Danny Altmann |
| 36 |
[GO] |
2024―Jul―25 |
INFβ therapy for COVID-19: the new SNG001 drug |
Stephen Holgate |
| 37 |
[GO] |
2024―Jul―25 |
Identification of a new coronavirus-specific RNA export protein complex |
Montse Bárcena-Martin |
| 38 |
[GO] |
2024―Jul―25 |
SARS-CoV and other emerging coronaviruses |
Ralph Baric |
| 39 |
[GO] |
2024―Jul―25 |
Nanotechnologies in the fight against coronaviruses |
Sabine Szunerits |
| 40 |
[GO] |
2024―Jul―25 |
A novel AIOD-CRISPR system for diagnosis of SARS-CoV-2 |
Changchun Liu |
| 41 |
[GO] |
2024―Jul―25 |
Development of an intranasal vaccine for SARS-CoV-2 |
Scot Roberts |
| 42 |
[GO] |
2024―Jul―25 |
The evolutionary origin of SARS-CoV-2 |
Feng Gao |
| 43 |
[GO] |
2024―Jul―25 |
Approaches for elucidating genetic susceptibility to SARS-CoV-2 |
Kenneth Baillie |
| 44 |
[GO] |
2024―Jul―25 |
Interspecies transmission of SARS-CoV-2 |
Dalan Bailey |
| 45 |
[GO] |
2024―Jul―25 |
The role of short linear motifs (SLiMs) in SARS-CoV-2 entry into human cells |
Toby Gibson |
| 46 |
[GO] |
2024―Jul―25 |
SARS-CoV-2 evolution within and between individuals |
Katia Koelle |
| 47 |
[GO] |
2024―Jul―25 |
SARS-CoV-2 evolution: emergence of the ‘Californian’ and ‘Indian’ variants |
Eric Vail |
| 48 |
[GO] |
2024―Jul―25 |
SARS-CoV-2 human monoclonal antibody therapy |
James Crowe |
| 49 |
[GO] |
2024―Jul―25 |
SARS-COV-2 human monoclonal antibody therapy update |
James Crowe |
| 50 |
[GO] |
2024―Jul―25 |
An FDA approved salivary test for SARS-CoV-2 infection |
Andrew Brooks |
| 51 |
[GO] |
2024―Jul―25 |
Potential long-term health effects of a SARS-CoV-2 infection |
Danny Altmann |
| 52 |
[GO] |
2024―Jul―25 |
The cardiovascular complications of SARS-CoV-2 infection |
Srihari Naidu |
| 53 |
[GO] |
2024―Jul―25 |
SARS-CoV-2 monoclonal antibody testing in vivo |
Michael Diamond |
| 54 |
[GO] |
2024―Jul―25 |
SARS-CoV-2 mutations: phenotypes and implications for vaccine development |
David Montefiori |
| 55 |
[GO] |
2024―Jul―25 |
The emergence of the SARS-CoV-2 Omicron variant |
Emma Thomson |
| 56 |
[GO] |
2024―Jul―25 |
Identifying SARS-CoV-2 proteases |
Christa E. Müller, Michael Gütschow |
| 57 |
[GO] |
2024―Jul―25 |
ABO blood groups and SARS-CoV-2 susceptibility |
Sean Stowell |
| 58 |
[GO] |
2024―Jul―25 |
SARS-CoV-2 vaccine development |
Stanley Plotkin |
| 59 |
[GO] |
2024―Jul―25 |
SARS-CoV-2 vaccine development: where are we now? |
Gary Kobinger |
| 60 |
[GO] |
2024―Jul―25 |
SARS-CoV-2 vaccine rollout campaigns |
Luis Graca |
| 61 |
[GO] |
2024―Jul―25 |
SARS-CoV-2 vaccine: current biological targets and considerations |
Adolfo Garcia-Sastre |
| 62 |
[GO] |
2024―Jul―25 |
The development of SARS-CoV-2 vaccines |
Peter Hotez |
| 63 |
[GO] |
2024―Jul―25 |
Genetic surveillance and the emergence of SARS-CoV-2 variants |
Emma Thomson |
| 64 |
[GO] |
2024―Jul―25 |
SARS-CoV-2 variants: implications for immunity and vaccine development |
Danny Altmann |
| 65 |
[GO] |
2024―Jul―25 |
The immune system response to the SARS-CoV-2 virus |
Paul Klenerman |
| 66 |
[GO] |
2024―Jul―25 |
The current understanding of the biology of the SARS-CoV-2 virus |
Peter Palese |
| 67 |
[GO] |
2024―Jul―25 |
The paediatric response to the SARS-CoV-2 virus and what we can learn from it |
Sallie Permar |
| 68 |
[GO] |
2024―Jul―25 |
The immune system response to the SARS-CoV-2 virus: an update |
Paul Klenerman |
| 69 |
[GO] |
2024―Jul―25 |
The immune system response to the SARS-CoV-2 virus: December 2020 update |
Paul Klenerman |
| 70 |
[GO] |
2024―Jul―25 |
The immune system response to the SARS-CoV-2 virus: July 2020 update |
Paul Klenerman |
| 71 |
[GO] |
2024―Jul―25 |
The immune system response to the SARS-CoV-2 virus: March 2021 update |
Paul Klenerman |
| 72 |
[GO] |
2024―Jul―25 |
The role of Neuropilin-1 as a SARS-CoV-2-specific endocytosis potentiator |
Yohei Yamauchi |
| 73 |
[GO] |
2024―Jul―25 |
Presence and function of SARS-CoV-2-specific T-cells in recovered patients and healthy volunteers |
Nina Le Bert |
| 74 |
[GO] |
2024―Jul―25 |
SARS-CoV-2: What we need to know and possible future therapies |
Stanley Perlman |
| 75 |
[GO] |
2024―Jul―25 |
The making of an influenza pandemic |
Jonathan Van-Tam |
| 76 |
[GO] |
2024―Jul―25 |
Controlling pandemic flu |
John Oxford |
| 77 |
[GO] |
2024―Jul―25 |
Responding to pandemic influenza |
Jonathan Van-Tam, Chloe Sellwood |
| 78 |
[GO] |
2024―Jul―25 |
Influenza virus pandemics: past and future |
Peter Palese |
